{
    "clinical_study": {
        "@rank": "168345", 
        "arm_group": {
            "arm_group_label": "ALKS 5461", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a 52-week open-label study to evaluate the safety and tolerability of ALKS 5461."
        }, 
        "brief_title": "A Long-Term Safety Study of ALKS 5461", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Agree to use an approved method of contraception for the duration of the study\n\n          -  Have the potential to safely benefit from the administration of ALKS 5461\n\n          -  Have a diagnosis of major depressive disorder (MDD)\n\n          -  Additional criteria may apply\n\n        Exclusion Criteria:\n\n          -  Have a positive test for drugs of abuse\n\n          -  Currently pregnant or breastfeeding\n\n          -  Have a current primary Axis-I disorder other than MDD\n\n          -  Have used opioid agonists (eg, codeine, oxycodone, tramadol, morphine) or opioid\n             antagonists (eg, naloxone, naltrexone) within 14 days\n\n          -  Have received electroconvulsive therapy treatment within the last 2 years, or\n             received more than 1 course of electroconvulsive treatment during their lifetime\n\n          -  Have attempted suicide within the past 2 years\n\n          -  Have a history of intolerance, allergy, or hypersensitivity to buprenorphine or\n             opioid antagonists (eg, naltrexone, naloxone)\n\n          -  Have had a significant blood loss or blood donation within the past 60 days\n\n          -  Additional criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1700", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02141399", 
            "org_study_id": "ALK5461-208"
        }, 
        "intervention": {
            "arm_group_label": "ALKS 5461", 
            "description": "Sublingual tablet, taken daily", 
            "intervention_name": "ALKS 5461", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 15, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Atlanta", 
                    "country": "United States", 
                    "state": "Georgia", 
                    "zip": "30308"
                }, 
                "name": "Alkermes Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 3 Multicenter Study of the Long-Term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults Who Have an Inadequate Response to Antidepressant Therapy (the FORWARD-2 Study)", 
        "overall_official": {
            "affiliation": "Alkermes", 
            "last_name": "Randall Marshall, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety and tolerability will be assessed by number and percentage of subjects with adverse events (AEs)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 56 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02141399"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Alkermes", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alkermes", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}